China, Nov. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, double-cohort, phase II clinical study of Trastuzumab Rezetecan + mFOLFOX6 or Retlirafusp alfa + CapOX for neoadjuvant treatment of colon cancer with different HER2 statuses'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600136742
Registration Time: 2026/11/15
Type: Interventional study
Primary Sponsor: Jiangsu Cancer Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=353273
Published by HT Digital Content Services with permission from Health Daily Digest....